GlassScriptPhysician profile
Elizabeth Nathan
NPI 1447745930
$1,598.25
in general payments reported to CMS, 2019-2025
19 companies · $671 in 2025
The $671 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.82 · 2022: $264 · 2023: $557 · 2024: $57.36 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,285.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $262.41 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $225.96 | 2022-2025 | |
| Novo Nordisk INC | $225.24 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $213.89 | 2022-2025 | Evenity, Repatha, Prolia |
| Glaxosmithkline, LLC. | $106.87 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Madrigal Pharmaceuticals | $102.86 | 2024-2025 | Rezdiffra, Resmetirom |
| Bayer Healthcare Pharmaceuticals INC. | $81.31 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $73.35 | 2021-2023 | Xarelto |
| Idorsia Pharmaceuticals US INC | $46.60 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $44.94 | 2025 | Voquezna |
| Exact Sciences Corporation | $42.36 | 2025 | Cologuard Collection Kit |
| Dexcom, INC. | $35.27 | 2023-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $29.10 | 2023-2025 | Airsupra, Farxiga |
| Insmed, INC. | $24.58 | 2025 | Brinsupri |
| Astellas Pharma US INC | $19.02 | 2025 | Veozah |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $17.42 | 2022 | |
| Pfizer INC. | $16.99 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $16.82 | 2025 | Zoryve |
| Merck Sharp & Dohme LLC | $13.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Nathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.